Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development

In 2021, the US Food and Drug Administration (FDA) granted approval to aducanumab, an antiamyloid antibody for early-stage Alzheimer's disease, despite a lack of clear clinical evidence demonstrating the drug's cognitive benefits. The manufacturer initially priced the drug at a staggering...

Descripción completa

Detalles Bibliográficos
Autores principales: Brockmann, Rouen, Nixon, Joanna, Love, Bryan L., Yunusa, Ismaeel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996432/
https://www.ncbi.nlm.nih.gov/pubmed/36908502
http://dx.doi.org/10.1016/j.lana.2023.100467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996432/
https://www.ncbi.nlm.nih.gov/pubmed/36908502
http://dx.doi.org/10.1016/j.lana.2023.100467

Ejemplares similares